RxSight shareholder files class action lawsuit alleging financial misrepresentation.

A shareholder has filed a securities class action lawsuit against RxSight, Inc. (NASDAQ: RXST) on behalf of investors who purchased or acquired the company's securities between November 7, 2024, and July 8, 2025. The lawsuit alleges that RxSight overstated product demand and failed to disclose that the company was experiencing issues. Investors who purchased RxSight securities during this period and lost money may be eligible to join the class action lawsuit.

A shareholder has filed a securities class action lawsuit against RxSight, Inc. (NASDAQ: RXST) on behalf of investors who purchased or acquired the company's securities between November 7, 2024, and July 8, 2025. The lawsuit alleges that RxSight overstated product demand and failed to disclose that the company was experiencing issues. Investors who purchased RxSight securities during this period and lost money may be eligible to join the class action lawsuit.

The complaint, filed in the U.S. District Court for the Central District of California, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. It alleges that RxSight made false and misleading statements and failed to disclose material information, including adoption challenges, structural issues, and overstated product demand [1].

The lawsuit seeks to recover losses on behalf of investors who were adversely affected by the alleged securities fraud. Investors have until September 22, 2025, to request that the Court appoint them as lead plaintiffs [2]. The lead plaintiff will represent the class members in directing the litigation, and the Rosen Law Firm assures investors that there is no cost or obligation to participate [3].

The class action lawsuit comes amid significant financial setbacks for RxSight. On July 8, 2025, after the market closed, the company reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [4]. The news led to a substantial drop in RxSight's stock price, falling $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025 [4].

Investors who believe they have suffered losses due to RxSight's alleged securities fraud are encouraged to contact legal counsel for more information. The Rosen Law Firm, Faruqi & Faruqi, LLP, and Levi & Korsinsky, LLP are among the firms representing investors in this class action lawsuit. Each firm has a track record of recovering millions of dollars for investors in similar cases [3][4].

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130886/0/en/RXST-COURT-NOTICE-RxSight-Inc-Investors-may-have-been-Affected-by-Fraud-Contact-BFA-Law-before-September-22-if-You-Suffered-Losses-NASDAQ-RXST.html
[2] https://www.marketscreener.com/news/faruqi-faruqi-reminds-rxsight-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-ce7c5ed2d981fe24
[3] https://www.ainvest.com/news/rxsight-investors-entitled-compensation-class-action-lawsuit-2508/
[4] https://www.globenewswire.com/news-release/2025/08/08/3130393/3080/en/Class-Action-Filed-Against-RxSight-Inc-RXST-Seeking-Recovery-for-Investors-Contact-Levi-Korsinsky.html